Norway, June 16 -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has signed a strategic agreement for supply of Thorium-228 to a global leader in targeted alpha therapy.The five-year supply agreement represents revenues of approximately NOK 200 million (USD 20 million) for Thor Medical, with a phased ramp-up of supply in accordance with the planned commissioning and scaling of the company's AlphaOne plant, currently under construction.Thorium-228 is a precursor for Pb-212, which is widely regarded as one of the most promising radioisotopes for use in next-generation precision cancer treatments. The undisclosed partner is progressing an extensive portfolio of targeted alpha th...